Pfizer Inc. Press Releases https://investors.pfizer.com/generated by Q4Fri, 24 Jul 2026 18:23:07 -0400Copyright Q4 Inc. All rights reserved.FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer78120731-395b-4326-9787-ded62b98b508https://investors.pfizer.com/Investors/news-events/News/news-details/2026/FDA-Grants-Priority-Review-for-Pfizers-TALZENNA-Plus-XTANDI-for-the-Treatment-of-Metastatic-Prostate-Cancer/default.aspxWed, 22 Jul 2026 16:30:00 -0400U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityc49246f8-963d-4061-8608-7facf0ea1ee4https://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Approves-PADCEV-plus-Keytruda-as-Neoadjuvant-and-Adjuvant-Treatment-for-Muscle-Invasive-Bladder-Cancer-Regardless-of-Cisplatin-Eligibility/default.aspxFri, 10 Jul 2026 11:23:00 -0400Pfizer Declares Third-Quarter 2026 Dividendfc2cb221-1792-4747-82e3-48d8cce2a497https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Declares-Third-Quarter-2026-Dividend/default.aspxWed, 24 Jun 2026 15:52:00 -0400FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance65c761b5-5f36-42f2-a649-654adbdb9146https://investors.pfizer.com/Investors/news-events/News/news-details/2026/FDA-Approves-Pfizers-IBRANCE-Regimen-for-HR-HER2-Metastatic-Breast-Cancer-Frontline-Maintenance/default.aspxWed, 24 Jun 2026 14:10:00 -0400Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts4aad6983-402e-489b-913a-23ea37ac4e10https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-August-4-Conference-Call-with-Analysts/default.aspxTue, 23 Jun 2026 10:00:00 -0400Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer1e3b074e-9ea5-4e70-9f7e-914731fdee5chttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Announces-Topline-Phase-3-Results-for-Sigvotatug-Vedotin-in-Previously-Treated-Metastatic-Non-Squamous-Non-Small-Cell-Lung-Cancer/default.aspxMon, 22 Jun 2026 16:30:00 -0400Pfizer Announces Chief Financial Officer Transitionf0f09535-e028-4448-ad63-eea921158752https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Announces-Chief-Financial-Officer-Transition/default.aspxThu, 18 Jun 2026 06:45:00 -0400U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need3ee46cb7-8b33-4eec-8f0d-24228c183568https://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Approves-Pfizers-HYMPAVZI-for-the-Treatment-of-Two-Additional-Hemophilia-A-or-B-Patient-Populations-with-Significant-Medical-Need/default.aspxMon, 08 Jun 2026 06:45:00 -0400Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatideb34139a9-2761-471e-b4ed-856546c5020ehttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide/default.aspxSat, 06 Jun 2026 09:00:00 -0400Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference90f19d6b-0f02-43f5-a327-74008e130f68https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference-d15093844/default.aspxMon, 01 Jun 2026 10:00:00 -0400